News ArticleMore News »
Novum’s Pina D’Angelo Was Invited to Present at FDA’s OBRC Seminar
Aug 8, 2017
Pittsburgh, PA: Pina D’Angelo, MSc, Novum’s Executive Director, Scientific Affairs (Biostatistics), spoke at the invitation-only FDA Office of Bioequivalence Reviewer Club seminar on August 16, 2017. Her presentation, “Testing for bioequivalence in higher-order crossover designs: two-at-a-time principle versus pooled ANOVA”, will examine which method of statistical analysis is more appropriate to conclude bioequivalence in higher-order crossover studies.
Celebrating over 40 years in business, Novum is considered an industry leader in the full-service conduct of clinical trials. Novum’s applies its scientific, technical, and operational knowledge to over 200 early phase projects annually, from bioequivalence to 505(b)(2) to FIH. Novum also manages complex late phase research studies in patient populations across multiple therapeutic areas.